Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA. METHODS: Data were pool...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Ann Rheum Dis
Prif Awduron: Cohen, Stanley B, Tanaka, Yoshiya, Mariette, Xavier, Curtis, Jeffrey R, Lee, Eun Bong, Nash, Peter, Winthrop, Kevin L, Charles-Schoeman, Christina, Thirunavukkarasu, Krishan, DeMasi, Ryan, Geier, Jamie, Kwok, Kenneth, Wang, Lisy, Riese, Richard, Wollenhaupt, Jürgen
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Publishing Group 2017
Pynciau:
Clinical and Epidemiological Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5530353/
https://ncbi.nlm.nih.gov/pubmed/28143815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2016-210457
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg